Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01519713
Other study ID # MTA76 (SFY12080)
Secondary ID U1111-1124-7479
Status Completed
Phase Phase 3
First received January 20, 2012
Last updated May 22, 2013
Start date January 2012
Est. completion date December 2012

Study information

Verified date May 2013
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority Japan: Pharmaceuticals and Medical Devices Agency
Study type Interventional

Clinical Trial Summary

This study is designed to assess the safety and immunogenicity of a single dose of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) to support registration of the product in Japan.

Primary Objective:

- To describe the seroprotection rate [% of subjects with serum bactericidal assay using baby rabbit complement (SBA-BR) ≥1:128] to meningococcal antigens (serogroups A, C, Y and W-135) following vaccination with SP284 vaccine in subjects 2 through 55 years of age

Secondary Objectives:

- To describe the safety following receipt of SP284 vaccine in subjects 2 through 55 years of age

- To describe the immune responses to meningococcal antigens (serogroups A, C, Y and W-135) following vaccination with SP284 vaccine in subjects 2 through 55 years of age.


Description:

All participants will receive a single injection of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine on Day 0 and undergo immunogenicity assessment and safety monitoring post-vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date December 2012
Est. primary completion date September 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 2 Years to 55 Years
Eligibility Inclusion Criteria:

- Aged 2 through 55 years on the day of inclusion

- For subjects = 20 years of age: Informed consent form has been signed and dated by the subjects. For subjects 2 to 19 years of age: Informed consent form has been signed and dated by the parent(s) or other legal representative. Also subjects 7 to 11 years of age will provide assent and subjects 12 to 19 years of age will provide written assent form.

- Able to attend all scheduled visits and to comply with all trial procedures

- For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination.

Exclusion Criteria:

- Any acute and/or serious disease/illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion

- History of meningococcal diseases, confirmed either clinically, serologically, or microbiologically

- Known systemic hypersensitivity to any of the vaccine components, or history of a life threatening reaction to a vaccine containing the same substances of the study vaccine

- Known or suspected congenital or current/ previous acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)

- Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial inclusion

- Planned participation in another clinical trial during the present trial period

- Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response

- Receipt of any vaccine within the four weeks preceding the trial vaccination, except for influenza vaccination, which may be received at least two weeks before the study vaccine

- Planned receipt of any vaccine during the trial period

- Clinical or known serological evidence of systemic illness including hepatitis B, hepatitis C and/or human immunodeficiency virus (HIV) infection

- Ineligible according to the investigator's clinical judgment

- Known pregnancy, or suspected pregnancy or a positive (serum and/or urine) pregnancy test

- Currently breast feeding a child

- Known thrombocytopenia, contraindicating intramuscular (IM) vaccination

- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination

- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily

- Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures

- Identified as employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family member (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator

- Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine

- History of Guillain-Barré Syndrome.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Biological:
Meningococcal polysaccharide diphtheria toxoid conjugate
0.5 mL, Intramuscular

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers of >=1:128 Following Vaccination With One Dose of Menactra® Vaccine Functional antibody activity against meningococcal serogroups A, C, Y and W-135 antigens were determined by using a serum bovine assay using a baby rabbit complement (SBA-BR). Sero protection was defined as SBA-BR titer of = 1:128. 28 Days post-vaccination No
Secondary Number of Participants With Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers of >=1:8 Following Vaccination With One Dose of Menactra® Vaccine Functional antibody activity against meningococcal serogroups A, C, Y and W-135 antigens were determined by using a serum bovine assay using a baby rabbit complement (SBA-BR). 28 Days post-vaccination No
Secondary Number of Participants With a 4-Fold Rise in Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers on Day 28 From Day 0 Following Vaccination With One Dose of Menactra® Vaccine. Functional antibody activity against meningococcal serogroups A, C, Y and W-135 antigens were determined by using a serum bovine assay using a baby rabbit complement (SBA-BR). 28 Days post-vaccination No
Secondary Serum Bovine Albumin Baby Rabbit (SBA-BR) Geometric Mean Titers Following Vaccination With One Dose of Menactra® Vaccine Functional antibody activity against meningococcal serogroups A, C, Y and W-135 antigens were determined by using a serum bovine assay using a baby rabbit complement (SBA-BR). Days 0 and 28 post-vaccination No
Secondary Serum Bovine Albumin Baby Rabbit (SBA-BR) Geometric Mean of Individual Titer Ratio Following Vaccination With One Dose of Menactra® Vaccine Functional antibody activity against meningococcal serogroups A, C, Y and W-135 antigens were determined by using a serum bovine assay using a baby rabbit complement (SBA-BR). 28 Days post-vaccination No
Secondary Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reactions Following Vaccination With One Dose of Menactra® Vaccine Solicited injection site reactions: Pain, Erythema and Swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia.
Grade 3 solicited reactions were defined as: Pain incapacitating (children) and prevents daily activities (adolescents and adults). Fever = 39.0°C; Headache, Malaise and Myalgia, significant, prevents daily activities.
Day 0 up to Day 28 post-vaccination No
See also
  Status Clinical Trial Phase
Withdrawn NCT03445416 - Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men N/A
Completed NCT02526394 - Pertussis and Meningitis C Concomitant Vaccination in Adolescents Phase 4
Completed NCT01442675 - Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine Phase 2
Completed NCT00539032 - Immunology and Safety of Menactra® in Children in Saudi Arabia Phase 3
Terminated NCT00428051 - Colombia Epidemiologic Surveillance Study N/A
Recruiting NCT05496673 - Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda N/A
Completed NCT02003495 - Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine Phase 3
Recruiting NCT00901602 - Lebanese Interhospital Pneumococcal Surveillance Program
Completed NCT00850603 - Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® Phase 4
Completed NCT02591290 - Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Phase 4
Completed NCT03112031 - Treatment With Tamoxifen in Cryptococcal Meningitis Phase 2
Completed NCT02881957 - Hypovitaminosis D in Neurocritical Patients Phase 2/Phase 3
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Completed NCT03378258 - Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Recruiting NCT05637645 - Different Approaches of Spinal Anesthesia in Patients Undergoing Cesarean Section N/A
Completed NCT02841254 - Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies N/A
Completed NCT02003313 - Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine Phase 3
Recruiting NCT01619462 - Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children Phase 3
Completed NCT01239043 - Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination Phase 2
Completed NCT00495690 - Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease Phase 3

External Links